[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2018;68(6):394-424.
[2] Katoh H, Yamashita K, Enomoto T, Watanabe M. Classification and general considerations of thyroid cancer., Ann Clin Pathol. 2015;3(1):1045.
[3] Liu R, Zhang T, Zhu G, Xing M. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer., Nature communications. 2018;9(1):579.
[4] Teng H, Mao F, Liang J, Xue M, Wei W, Li X, et al. Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma., Theranostics. 2018;8(16):4345.
[5] Brennan K, Holsinger C, Dosiou C, Sunwoo JB, Akatsu H, Haile R, et al. Development of prognostic signatures for intermediate-risk papillary thyroid cancer. BMC cancer. 2016;16(1):736.
[6] Menschikowski M, Hagelgans A, Nacke B, Jandeck C, Sukocheva O, Siegert G. Epigenetic control of phospholipase A 2 receptor expression in mammary cancer cells. BMC cancer. 2015;15(1):971.
[7] Salazar M, Lorente M, García-Taboada E, Gomez EP, Dávila D, Zúñiga-García P, et al. Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation. Cell death and differentiation. 2015;22(1):131.
[8] Lu C, Mishra A, Zhu YJ, Meltzer P, Cheng S-y. Genomic profiling of genes contributing to metastasis in a mouse model of thyroid follicular carcinoma. American journal of cancer research. 2011;1(1):1.
[9] Rodriguez MdCP, Freire MdCC, Cameselle-Teijeiro JM, Puente FD, Figueroa AV. Methods for diagnosing follicular thyroid cancer. Google Patents; 2012.
[10] Song J, Yang Z. Case report: Whole exome sequencing of circulating cell-free tumor DNA in a follicular thyroid carcinoma patient with lung and bone metastases. Journal of circulating biomarkers. 2018;7:1849454418763725.
[11] Cerutti JM, Oler G, Michaluart P, Delcelo R, Beaty RM, Shoemaker J, et al. Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer research. 2007;67(16):7885-92.
[12] Qian Z, Qingshan C, Chun J, Huijun Z, Feng L, Qiang W, et al. High Expression of TNFSF13 in Tumor Cells and Fibroblasts Is Associated With Poor Prognosis in Non–Small Cell Lung Cancer. American journal of clinical pathology. 2014;141(2):226-33.
[13] Blanco CG, Matute EM, de Leiva Hidalgo A. Molecular biomarkers involved in the tumor dedifferentiation process of thyroid carcinoma of epithelial origin: perspectives. Endocrinología y Nutrición (English Edition). 2012;59(7):452-8.
[14] Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proceedings of the National Academy of Sciences. 2001;98(26):15044-9.
[15] Niedźwiecki S, Stępień T, Kuzdak K, Stępień H, Krupiński R, Seehofer D, et al. Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbeck’s archives of surgery. 2008;393(3):275-80.
[16] Chen F, Liu X, Bai J, Pei D, Zheng J. The emerging role of RUNX3 in cancer metastasis. Oncology reports. 2016;35(3):1227-36.
[17] Joung KH, Shong M.Epigenetic regulation of RUNX3 in thyroid carcinoma. The Korean journal of internal medicine. 2012;27(4):391.
[18] dos Reis M, Beltrami C, Kowaslki L, Rogatto S. Epigenetic alterations in well-differentiated thyroid cancer. J Clin Epigenet. 2016;1:1.
[19] Moarii M, Boeva V, Vert J-P, Reyal F. Changes in correlation between promoter methylation and gene expression in cancer. BMC genomics. 2015;16(1):873.
[20] Celano M, Rosignolo F, Maggisano V, Pecce V, Iannone M, Russo D, et al. MicroRNAs as biomarkers in thyroid carcinoma. International journal of genomics. 2017;2017.
[21] Poulios E, Zografos G, Tseleni-Balafouta S, Linos D. Identification of a Novel, Diagnostic microRNA Signature in Papillary Thyroid Cancer. Journal of Medical & Surgical Pathology. 2018, 3(3): 162.
[22] Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2012;97(6):2084-92.
[23] Saiselet M, Pita JM, Augenlicht A, Dom G, Tarabichi M, Fimereli D, et al. miRNA expression and function in thyroid carcinomas: a comparative and critical analysis and a model for other cancers. Oncotarget. 2016;7(32):52475.
[24] Gottfried, Y., et al., Expression of the pro‐apoptotic protein ARTS in astrocytic tumors: Correlation with malignancy grade and survival rate. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2004. 101(11): p. 2614-2621.
[25] Love, M.I., W. Huber, and S. Anders, Moderated estimation of fold change and dispersion for RNAseq data with DESeq2. Genome biology, 2014. 15(12): p. 550.
[26] Chen, E.Y., et al., Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC bioinformatics, 2013. 14(1): p. 128.
[27] Zhang, P., et al., Association of miR‐1247‐5p expression with clinicopathological parameters and prognosis in breast cancer. International journal of experimental pathology, 2018. 99(4): p. 199-205.
[28] Fang, T., et al., Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nature communications, 2018. 9(1): p. 191.
[29] Mancikova, V., et al., MicroRNA deep-sequencing reveals master regulators of follicular and papillary thyroid tumors. Modern Pathology, 2015. 28(6): p. 748.
[30] Acquaviva, G., et al., Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. Histopathology, 2018. 72(1): p. 6-31.
[31] Agrawal, N., et al., Integrated genomic characterization of papillary thyroid carcinoma. Cell, 2014.159(3): p. 676-690.
[32] Haraldsdottir, S. and M.H. Shah, New era for treatment in differentiated thyroid cancer. The Lancet, 2014. 384(9940): p. 286-288.
[33] Kanehisa, M., et al., KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic acids research, 2016. 45(D1): p. D353-D361.
[34] UniProt: the universal protein knowledgebase. Nucleic acids research, 2016. 45(D1): p. D158-D169.
[35] Seliger, C., et al., Lactate-modulated induction of THBS-1 activates transforming growth factor (TGF)-beta2 and migration of glioma cells in vitro. PloS one, 2013. 8(11): p. e78935.
[36] Amoli, M.M., et al., HLA-DR association in papillary thyroid carcinoma. Disease markers, 2010. 28(1): p. 49-53.
[37] Jo, Y.S., et al., Significance of the expression of major histocompatibility complex class II antigen, HLA‐DR and‐DQ, with recurrence of papillary thyroid cancer. International journal of cancer, 2008. 122(4): p. 785-790.
[38] Soini, Y., P. Pääkkö, and V. Lehto, Histopathological evaluation of apoptosis in cancer. The American journal of pathology, 1998. 153(4): p. 1041-1053.
[39] Liyanarachchi, S., et al., Genome-wide expression screening discloses long noncoding RNAs involved in thyroid carcinogenesis. The Journal of Clinical Endocrinology & Metabolism, 2016. 101(11): p. 4005-4013.